Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00794950 Phase II Sunitinib Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma Completed USA 0
NCT01688999 Phase II Cabozantinib Cabozantinib for Advanced Urothelial Cancer Completed USA 0
NCT03106610 Phase I Nivolumab Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy Terminated USA 0
NCT03549715 Phase Ib/II Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Tremelimumab + Vinblastine Cisplatin + Doxorubicin + Durvalumab + Methotrexate + Vinblastine NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO) Active, not recruiting FRA 0
NCT04506554 Phase II Cisplatin + Doxorubicin + Methotrexate + Nivolumab + Vinblastine A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer Suspended USA 0